Connect with us

Health

Cancer vaccine shows promising results for certain patients

Published

on

Cancer vaccine shows promising results for certain patients

There could be new hope on the horizon for kidney cancer patients in the form of an experimental vaccine.

Researchers at Dana-Farber Cancer Institute, Harvard Medical School, Yale Cancer Center and other universities have announced early findings from a study of an anti-tumor vaccine for patients with advanced kidney cancer.

“Patients with stage 3 or 4 kidney cancer are at high risk of recurrence,” said co-senior author and co-principal investigator Toni Choueiri, MD, director of the Lank Center for Genitourinary Cancer at Dana-Farber, in a press release.

Advertisement

DISEASE STARTS ON YOUR PLATE, CARDIOLOGIST SAYS — HERE’S WHAT TO CHANGE

“The tools we have to lower that risk are not perfect, and we are relentlessly looking for more.”

There could be new hope on the horizon for kidney cancer patients in the form of an experimental vaccine. (iStock)

After undergoing surgery to remove a malignant tumor, the study’s nine participants received a cancer vaccine that was intended to “train” their immune systems to identify and attack any lingering cancer cells, according to the press release.

Each vaccine was personalized to match the individual patient’s tumor type based on cancer cells that were removed during surgery. These cells contain “neoantigens,” which are “tiny fragments of mutant proteins,” the release stated. The researchers used “predictive algorithms” to determine which neoantigens should be included in the vaccine to provide the highest level of immunity. 

Advertisement

PROSTATE CANCER CASES SPIKE IN THIS US STATE AS DOCTORS SHARE LIKELY REASON

Five of the patients also received ipilimumab, a type of immunotherapy drug.

All nine patients showed a “successful anti-cancer immune response” after getting the vaccine. After an average of 34.7 months, they all remained cancer-free.

Within three weeks of receiving the vaccine, patients showed an “immune response,” with T-cells spiking by more than 166 times, the release said. (T-cells, also known as T lymphocytes, are immune cells that help to fight cancer and prevent infection.)

“The tools we have to lower that risk are not perfect and we are relentlessly looking for more.”

Advertisement

In the study, the T cells were found to remain in the patient’s body for up to three years and attacked the existing tumor cells.

“We observed a rapid, substantial, and durable expansion of new T cell clones related to the vaccine,” said Patrick Ott, MD, PhD, director of the Center for Cancer Vaccines at Dana-Farber.

“These results support the feasibility of creating a highly immunogenic personalized neoantigen vaccine in a lower mutation burden tumor and are encouraging, though larger-scale studies will be required to fully understand the clinical efficacy of this approach.”

For most stage 3 or 4 kidney cancer patients, the standard treatment is surgical removal of the tumor, which is often followed by an immunotherapy drug. (iStock)

The results of the clinical trial were reported in the journal Nature on Feb. 5. 

Advertisement

“We’re very excited about these results, which show such a positive response in all nine patients with kidney cancer,” Choueiri noted.

For most stage 3 or 4 kidney cancer patients, the standard treatment is surgical removal of the tumor, which is often followed by an immunotherapy drug called Pembrolizumab (Keytruda).

COMMON CANCER TYPE COULD BE DETECTED WITH NEW BLOOD TEST

“Pembrolizumab induces an immune response that reduces the risk of the cancer coming back,” according to Dana-Farber. “However, about two-thirds of patients can still recur and have limited treatment options.”

First author David A. Braun, MD, PhD, a medical oncologist and physician-scientist at Yale Cancer Center and Yale School of Medicine, noted that the approach used in this study was “truly distinct from vaccine attempts in kidney cancer.”

Advertisement

“We pick targets that are unique to the cancer and different from any normal part of the body, so the immune system can be effectively ‘steered’ toward the cancer in a very specific way,” a researcher said in the release.  (iStock)

“We pick targets that are unique to the cancer and different from any normal part of the body, so the immune system can be effectively ‘steered’ toward the cancer in a very specific way,” Braun said in the release. 

“We learned which specific targets in the cancer are most susceptible to immune attack and demonstrated that this approach can generate long-lasting immune responses, directing the immune system to recognize cancer. We believe this work can form a foundation for the development of neoantigen vaccines in kidney cancer.”

‘Exciting and promising’

Charles Nguyen, MD, a medical oncologist who specializes in kidney cancer at City of Hope in Orange County, California, noted that kidney cancer is among the 10 most common cancers among men and women in the U.S. 

“This is a very exciting and promising tool for many of our patients with kidney cancer, where we can one day make a cure possible for all.”

Advertisement

“Patients with early stage (localized) kidney cancer are often first treated with surgery to remove the tumor — however, many patients have a risk of the cancer coming back years after surgery, and there is a great interest in finding ways to lower the risk of cancer recurrence,” Nguyen, who was not involved in the study, told Fox News Digital.

“This exciting clinical trial evaluated a personalized cancer vaccine that uses genetic information from each patient’s cancer to train and enhance the patient’s immune system to recognize the cancer and prevent it from recurring.” 

      

While Nguyen acknowledged that this was a small study, all nine patients who received the vaccine were cancer-free even three years later. 

“This is a very exciting and promising tool for many of our patients with kidney cancer, where we can one day make a cure possible for all.”

Advertisement

Side effects and limitations

Some patients did experience side effects from the vaccine, including local reactions at the vaccine injection site and flu-like symptoms, although “no higher-grade side effects were reported.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The researchers also acknowledged that there were some limitations associated with the study.

“There were limitations in the antigen-prediction tools available at the time and in the ability to target only a single antigen,” they wrote.

Some patients did experience side effects from the vaccine, including local reactions at the vaccine injection site and flu-like symptoms. (IStock)

Advertisement

“Moreover, it was conducted in the setting of active metastatic disease in a number of study participants.”

Future research with larger clinical trials are planned to confirm the vaccine’s effectiveness and full potential, the release stated. 

For more Health articles, visit www.foxnews.com/health

Funding for this study was provided by the Gateway for Cancer Research, the U.S. Department of Defense, Yale Cancer Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Trust Family Foundation, Michael Brigham, Pan-Mass Challenge, Hinda L. and Arthur Marcus Foundation, The Loker Pinard Fund for Kidney Cancer Research at Dana-Farber Cancer Institute, National Institutes of Health, Conquer Cancer Foundation/Sontag Foundation, the release stated.

Advertisement

Health

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause

Published

on

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause


Advertisement




Melissa Joan Hart Opens up About Weight Loss in Perimenopause | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Alzheimer’s prevention breakthrough found in decades-old seizure drug

Published

on

Alzheimer’s prevention breakthrough found in decades-old seizure drug

NEWYou can now listen to Fox News articles!

A drug that has long been used to treat seizures has shown promise as a potential means of Alzheimer’s prevention, a new study suggests.

The anti-seizure medication, levetiracetam, was first approved by the FDA in November 1999 under the brand name Keppra as a therapy for partial-onset seizures in adults. The approval has since expanded to include children and other types of seizures.

Northwestern University researchers recently found that levetiracetam prevented the formation of toxic amyloid beta peptides, which are small protein fragments in the brain that are commonly seen in Alzheimer’s patients.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons, according to the study findings, which were published in Science Translational Medicine.

Advertisement

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons. (iStock)

“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid‑beta 42 peptides and amyloid plaques,” said corresponding author Jeffrey Savas, associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine, in a press release. 

“Our new results uncovered new biology while also opening doors for new drug targets.”

HIDDEN BRAIN CONDITION MAY QUADRUPLE DEMENTIA RISK IN OLDER ADULTS, STUDY SUGGESTS

Advertisement

The brain is better able to avoid the pathway that produces toxic amyloid‑beta 42 proteins in younger years, but the aging process gradually weakens that ability, Savas noted. 

“This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he said. 

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease. (iStock)

That then leads to tau (“tangles”) — abnormal clumps of protein inside brain neurons — which can kill brain cells, trigger neuroinflammation and lead to dementia.

In order for levetiracetam to function as an Alzheimer’s blocker, high-risk patients would have to start taking it “very, very early,” Savas said — up to 20 years before elevated amyloid-beta 42 levels would be detected.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death,” the researcher noted.

The researchers also did a deep dive into previous human clinical data to determine whether Alzheimer’s patients who were taking the anti-seizure drug had slower cognitive decline. They reported that the patients in that category had a “significant delay” in the span from cognitive decline to death compared to those not taking the drug.

“This analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” the researcher said. (iStock)

“Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas said.

Advertisement

Looking ahead, the research team aims to find people who have genetic forms of Alzheimer’s to participate in testing, Savas said.

Limitations and caveats

The study had several limitations, including that it relied on animal models and cultured cells, with no human trials conducted.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Because the study was observational in nature, it can’t prove that the medication caused the prevention of the toxic brain proteins, the researchers acknowledged.

Savas noted that levetiracetam “is not perfect,” cautioning that it breaks down in the body very quickly.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The team is currently working to create a “better version” that would last longer in the body and “better target the mechanism that prevents the production of the plaques.”

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death.”

The medication’s common documented side effects include drowsiness, weakness, dizziness, irritability, headache, loss of appetite and nasal congestion.

It has also been linked to potential mood and behavior changes, including anxiety, depression, agitation and aggression, according to the prescribing information. In rare cases, it could lead to severe allergic reactions, skin reactions, blood disorders and suicidal ideation.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Funding for the study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund.

Fox News Digital reached out to the drug manufacturer and the researchers for comment.

Related Article

Alzheimer’s decline could slow dramatically with one simple daily habit, study finds
Continue Reading

Health

Seniors over 80 who eat specific diet may be less likely to reach 100 years old

Published

on

Seniors over 80 who eat specific diet may be less likely to reach 100 years old

NEWYou can now listen to Fox News articles!

Older adults who avoid meat in their golden years may be less likely to reach age 100 than their meat-eating counterparts, new research suggests.

Researchers tracked more than 5,000 adults aged 80 or older who were enrolled in the Chinese Longitudinal Healthy Longevity Survey.

Between 1998 and 2018, data showed that those who did not eat meat were less likely to reach their 100th birthday than those who consumed animal products regularly.

The findings seem to contradict previous studies that have linked vegetarianism and plant-based diets to lower risks of heart disease, stroke, diabetes and obesity.

Advertisement

Most evidence supporting the benefits of plant-based diets comes from studies tracking younger populations, the researchers noted. 

The findings contrast with previous research praising plant-based diets for their positive influence on heart health. (iStock)

The study, published in The American Journal of Clinical Nutrition, points to losses in muscle mass and bone density with age, shifts that can increase the risk of malnutrition and frailty in the “oldest old.”

As people enter their 80s and 90s, the nutritional priority often shifts from preventing long-term chronic diseases to maintaining day-to-day physical function, experts say.

HOW MUCH RED MEAT IS TOO MUCH? EXPERTS WEIGH IN ON FOOD PYRAMID UPDATES

Advertisement

“The headline ‘vegetarians over 80 less likely to reach 100’ sounds surprising, because it contrasts with decades of data linking plant‑forward diets to lower chronic disease risk earlier in life,” Erin Palinski-Wade, a New Jersey-based registered dietitian, told Fox News Digital. 

“However, once you see that this research is limited to adults over the age of 80 who are also underweight — and that this link disappears with the consumption of eggs, dairy and fish — the results are less surprising.”

While diets earlier in life tend to emphasize avoiding long-term disease, older age necessitates nutrients and weight maintenance, experts say. (iStock)

In those over 80, restricting animal proteins may be less likely to promote longevity, according to Palinski-Wade, who was not involved in the study.

Eliminating all animal protein — particularly in a population that may already experience diminished hunger cues — can make it more difficult to meet adequate protein needs, potentially increasing the risk of nutrient deficiencies, the nutritionist said.

Advertisement

ALZHEIMER’S SYMPTOMS COULD BE PREDICTED YEARS IN ADVANCE THROUGH ONE SIMPLE TEST

In addition to a higher tendency to be underweight, older populations also face a greater risk of bone fractures due to lower calcium and protein intake.

Potential limitations

The lower rate of vegetarians reaching 100 was only observed in participants identified as underweight, the researchers noted. No such association was found in people who maintained a healthy weight.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Because being underweight is already linked to greater frailty and mortality risk, the researchers noted that body weight may partly explain the findings, making it difficult to determine whether diet itself played a direct role.

Advertisement

Those incorporating animal-sourced products other than meat were just as likely to live to 100. (iStock)

Additionally, the shortened lifespans were not found in people who continued to eat non-meat animal products, such as fish, dairy and eggs. 

Older adults with these more flexible diets were just as likely to live to 100 as those eating meat, as these foods may provide the nutrients necessary for maintaining muscle and bone health, the researchers noted.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“This is an observational study, so it can only show associations, and does not prove that avoiding meat directly reduces the odds of reaching 100,” Palinski-Wade added.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

The researchers suggested that including small amounts of animal-sourced foods could help older seniors maintain essential nutrients and avoid the muscle loss often seen in those who stick strictly to plants.

Eliminating all animal protein — particularly in a population that may already experience diminished hunger cues — can make it more difficult to meet adequate protein needs, potentially increasing the risk of nutrient deficiencies. (iStock)

Palinski-Wade offered some guidance for those looking to optimize nutrition later in life.

“For adults in their 80s and beyond, especially anyone losing weight or muscle, the priority should be maintaining a healthy weight and meeting protein and micronutrient needs — even if that means adding or increasing fish, eggs, dairy or well‑planned, fortified plant proteins and supplements.”

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Strict vegan or very low‑protein patterns at that age should be carefully monitored by a dietitian or clinician, with attention to B12, vitamin D, calcium and total protein, according to Palinski-Wade.

“Younger and healthier adults can still confidently use plant‑forward or vegetarian patterns to lower long‑term chronic disease risk,” she added.

Related Article

Scientists reveal the one practice that could prevent dementia as you age
Continue Reading

Trending